Abbott Laboratories Form 4 insider transactions

Abbott Laboratories Director Robert J. Alpern acquired 58 stock equivalent units as part of his director compensation plan, increasing his total beneficial ownership to 10,300 units.

Abbott Laboratories' Vice President and Controller, John A. McCoy Jr., reported the disposition of 79 common shares for tax liability at $132.66 per share.

Abbott Laboratories' EVP and CFO, Philip P. Boudreau, disposed of 387 common shares to cover tax withholding obligations at a price of $132.66 per share.

Abbott Laboratories' EVP and CFO, Philip P. Boudreau, sold 5,550 common shares at a weighted average price of $134.551 per share under a pre-planned trading arrangement.

Abbott Laboratories Director John G. Stratton acquired 282 stock equivalent units on June 30, 2025, as part of his director compensation, bringing his total beneficial ownership to 12,315 units.

Abbott Laboratories Director Michael F. Roman acquired 271 stock equivalent units on June 30, 2025, increasing his beneficial ownership to 5,250 units.

Abbott Laboratories Director Patricia Paola Gonzalez reported the acquisition of 242 stock equivalent units on June 30, 2025, as part of her director compensation plan, increasing her total beneficial ownership to 4,655 units.

Abbott Laboratories Director Robert J. Alpern acquired 57 stock equivalent units on June 30, 2025, as part of director compensation, increasing his total beneficial ownership to 10,195 units.

An Executive Vice President at Abbott Laboratories reported a routine disposition of common shares to cover tax withholding obligations, while maintaining substantial beneficial ownership.

Elizabeth C. Cushman, EVP, General Counsel, and Secretary of Abbott Laboratories, was granted 3,790 performance-based restricted stock units and 14,680 stock options on June 27, 2025.

Director Sally E. Blount sold 2,600 shares of Abbott Laboratories common stock at a price of $129.66 on April 30, 2025.

Director John G. Stratton reports acquisition and disposal of Abbott Laboratories common shares and restricted stock units.

Director Daniel J. Starks reports acquisition of Abbott Laboratories common shares and stock options through incentive programs and a trust.

Director Michael F. Roman reports acquisition of 1,635 common shares of Abbott Laboratories through restricted stock units.

Director Michael O'Grady reports acquisition of restricted stock units and stock options in Abbott Laboratories.

Director Nancy McKinstry reports the acquisition of restricted stock units and a stock option grant from Abbott Laboratories on April 25, 2025.

Director Darren W. McDew acquired 1,635 common shares and restricted stock units in Abbott Laboratories on April 25, 2025.

Director Michelle Kumbier reports acquisition of restricted stock units and disposal of common shares in Abbott Laboratories.

Director Patricia Paola Gonzalez reports the acquisition of restricted stock units in Abbott Laboratories under the 2017 Incentive Stock Program.

Director Sally E. Blount reports acquisition of 1,635 restricted stock units in Abbott Laboratories under the 2017 Incentive Stock Program.

Director Claire Babineaux-Fontenot reports acquisition of restricted stock units and disposal of common shares of Abbott Laboratories.

Director Robert J. Alpern reports acquisition of 1,635 common shares of Abbott Laboratories through restricted stock units.

Director John G. Stratton acquired 277 stock equivalent units of Abbott Laboratories on March 31, 2025, as part of director fees credited to a grantor trust.

Director Michael F. Roman reports acquisition of stock equivalent units in Abbott Laboratories due to director fees.

Patricia Paola Gonzalez, a director at Abbott Laboratories, acquired 248 stock equivalent units on March 31, 2025, as part of director fees credited to a grantor trust.

Director Robert J. Alpern acquired 59 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.

Lisa D. Earnhardt, an Executive Vice President and Group President at Abbott Laboratories, reported exercising stock options and selling shares on March 6 and 7, 2025.

Retired EVP Andrea F. Wainer reports disposing of Abbott Laboratories shares on February 28, 2025, and March 3, 2025, following retirement.

Eric Shroff, a Senior Vice President at Abbott Laboratories, sold 562 common shares at $138.17 on March 3, 2025.

EVP and Group President of Abbott Laboratories, Daniel Gesua Sive Salvadori, reports disposing of 8,462 common shares to cover tax obligations.